
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, November 10th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will earn ($4.53) per share for the year, down from their prior forecast of ($4.48). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.62) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q4 2026 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.22) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($4.90) EPS, FY2028 earnings at ($4.07) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($0.44) EPS.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02.
Check Out Our Latest Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals stock opened at $40.48 on Thursday. The company has a 50-day simple moving average of $41.13 and a 200-day simple moving average of $52.13. Xenon Pharmaceuticals has a one year low of $33.38 and a one year high of $72.66.
Insider Buying and Selling at Xenon Pharmaceuticals
In related news, CFO Thomas Patrick Kelly bought 15,000 shares of the stock in a transaction on Wednesday, September 30th. The shares were purchased at an average price of $37.32 per share, with a total value of $559,800.00. Following the purchase, the chief financial officer owned 15,000 shares in the company, valued at approximately $559,800. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher Kenney sold 7,068 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the sale, the insider owned 2 shares in the company, valued at $120.50. This trade represents a 99.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.91% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP raised its holdings in Xenon Pharmaceuticals by 30.2% during the third quarter. Marshall Wace LLP now owns 897,509 shares of the biopharmaceutical company’s stock worth $33,378,000 after purchasing an additional 208,167 shares in the last quarter. HighVista Strategies LLC boosted its stake in Xenon Pharmaceuticals by 100.8% during the 3rd quarter. HighVista Strategies LLC now owns 70,908 shares of the biopharmaceutical company’s stock valued at $2,637,000 after purchasing an additional 35,590 shares in the last quarter. First Trust Advisors LP increased its position in shares of Xenon Pharmaceuticals by 17.8% during the 3rd quarter. First Trust Advisors LP now owns 10,377 shares of the biopharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,566 shares during the period. Cibc World Market Inc. increased its position in shares of Xenon Pharmaceuticals by 3.4% during the 3rd quarter. Cibc World Market Inc. now owns 20,632 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 672 shares during the period. Finally, Diversified Trust Co increased its position in shares of Xenon Pharmaceuticals by 4.9% during the 3rd quarter. Diversified Trust Co now owns 41,160 shares of the biopharmaceutical company’s stock valued at $1,531,000 after purchasing an additional 1,938 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.
Recent Xenon Pharmaceuticals Headlines
Investors following XENE have been watching these headlines:
- Neutral Sentiment: HC Wainwright retained its Buy rating on Xenon, offering a counterpoint to the lower forecasts. MarketBeat coverage
- Negative Sentiment: The analyst lowered projected EPS for Q4 2026 to ($1.14) and for 2027 to ($4.90) for the full year, with quarterly estimates of ($1.22) for Q2 and ($1.25) for Q4. The revisions point to slightly deeper expected losses. MarketBeat coverage
- Negative Sentiment: Longer-range forecasts were also reduced: EPS estimates moved to ($4.07) for 2028, ($2.25) for 2029 and ($0.44) for 2030. The largest revision was for 2030, from a prior estimate of ($0.18), suggesting profitability may take longer to reach. MarketBeat coverage
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
